Plain-English translation of NCT06085755 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two medications— (T-DXd) and —to see if they work better together against advanced stomach cancer. The study has two parts: the first part figures out the right dose of these medications when used together, and the second part tests whether that dose actually helps patients. This is for people whose cancer has a specific characteristic called HER2-low.
Advanced stomach cancer is hard to treat, especially when it has spread to other parts of the body or has come back after earlier treatment. Researchers believe that combining these two medications might work better than using them alone, since they attack cancer cells in different ways.
You likely qualify if…
You likely don't qualify if…
You will take two medications—one pill of three times a week and intravenous infusions of the other medication on a regular schedule. You'll have frequent visits in the first part of the study to check how you tolerate the combination, and then less frequent visits as the study continues. The trial includes blood tests and tumor scans (usually every 6 weeks at first, then every 12 weeks) to see if the treatment is working and to monitor your health.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
South Korea